Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 18/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.87 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939347 | 1.00 | HRH4 (1.00) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL29769889 | 0.93 | ALOX15 (1.00) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL602043 | 0.90 | HRH4 (0.81) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL603185 | 0.84 | HRH4 (0.73) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL602941 | 0.83 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL29404707 | 0.83 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Fumaric Acid SCHEMBL602943 | 0.83 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL20162482 | 0.83 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Jnj-7777120 SCHEMBL18486196 | 0.83 | HRH4 (0.80) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL13914874 | 0.81 | HRH4 (1.00) | HRH4HRH3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| CN-115803088-B | Cyclobenzaprine treatment of sexual dysfunction | 通尼克斯医药控股公司 | 2025-03-21 | — | — | CN | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| EP-4412602-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | Tonix Pharmaceuticals Holding Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-4294446-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | Agonex Biopharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230390215-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | claimed |
| WO-2023059728-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2023-04-13 | — | — | WO | claimed |
| CN-115803088-A | Cyclobenzaprine treatment of sexual dysfunction | 通尼克斯医药控股公司 | 2023-03-14 | — | — | CN | claimed |
| EP-4132648-A1 | CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION | Tonix Pharmaceuticals Holding Corp. (US) | 2023-02-15 | — | — | EP | claimed |
| WO-2022178120-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-12637452-B2 | Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097103-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2026-04-09 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3973961-A1 | USE OF HYDROXYZINE AND ANTIHISTAMINE ANALOGS FOR TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-03-30 | — | — | EP | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-20220040300-A1 | METHOD OF FILLING A CONTAINER WITH NO HEADSPACE | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | HRH4 4481/4885HRH3 3968/4885ALOX15 3805/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | HRH4 4405/4885HRH3 4233/4885ALOX15 1858/4885 |
| US-20260097103-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | CTRL, PREP, ANPEP | HRH4 4151/4885HRH3 3870/4885ALOX15 2062/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | HRH4 4319/4885HRH3 4397/4885ALOX15 2426/4885 |
| US-12637452-B2 | Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator | P2RX3, P2RX2, P2RX4 | HRH4 219/4885HRH3 151/4885ALOX15 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.